Context: Congenital hypothyroidism (CH) is the most common neonatal endocrine disorder, affecting one in 3000 to 4000 newborns. Since the introduction of a newborn screening program in 1988, more than 300 cases have been identified. The underlying genetic defects have not been systematically studied.
. More than 300 cases have been reported. The most common etiology is thyroid ectopy (50%), followed by dyshormonogenesis (26%) and athyreosis (24%) (3) .
CH is classified into two types: thyroid dysgenesis (70% to 80%) and thyroid dyshormonogenesis (20% to 30%) (4, 5) . In thyroid dysgenesis, defective thyroid gland development leads to athyreosis (without visible thyroid tissue in imaging studies; 35% to 40%), thyroid ectopy (frequently located in a sublingual position; 55% to 60%), and hypoplasia (a small thyroid or remnants of thyroid tissue in the normal position; 5%) (6) (7) (8) . Diseasecausing mutations have been reported in the thyroidstimulating hormone b (TSHB), thyroid-stimulating hormone receptor (TSHR), NK2 homeobox 1 (NKX2-1), NK2 homeobox 5 (NKX2-5), forkhead box E1 (FOXE1), paired box 8 (PAX8), and cell division cycle associated 8 (CDCA8) genes (5, (9) (10) (11) . A TSHB mutation results in central CH, which evades diagnosis in a TSHbased newborn screening program (12, 13 ). An NKX2-1 mutation can cause brain-thyroid-lung syndrome (14) . More than 13 TSHB, 49 TSHR, 51 NKX2-1, three NKX2-5, 29 PAX8, eight FOXE1, and three CDCA8 mutations have been reported in patients with hypothyroidism according to the Human Gene Mutation Database (HGMD; http://www.hgmd.cf.ac.uk/ac/index.php). The majority of NKX2-5 mutations result in congenital cardiac disease (87 mutations listed in the HGMD) (15) . Recently, mutations in a group of proteasome-related genes (PSMA1, PSMA3, PSMD2, and PSMD3) were found in patients with thyroid hemiagenesis, but their causative roles remain undetermined (16) .
In patients with thyroid dyshormonogenesis, the known genetic defects in thyroid hormone synthesis include mutations in the thyroglobulin (TG), thyroid peroxidase (TPO), dual oxidase 2 (DUOX2), dual oxidase maturation factor 2 (DUOXA2), sodium-iodide symporter or NIS (SLC5A5), pendrin (SLC26A4), and iodotyrosine deiodinase (IYD) genes. More than 89 TG, 103 TPO, 88 DUOX2, 14 DUOXA2, 14 SLC5A5, and four IYD mutations are listed in the HGMD. An SLC26A4 mutation causes Pendred syndrome, characterized by congenital bilateral sensorineural hearing loss and goiter with euthyroid or mild hypothyroidism. Although 110 mutations are listed in the HGMD, the disease is rarely detected by neonatal screening for CH; with sufficient dietary iodide, 90% of patients are euthyroid (4, 17) .
Currently, no information is available regarding the spectrum of mutations among Saudi patients with CH. In the current study, we performed molecular analysis of 55 patients with CH from 47 families by using nextgeneration exome sequencing (NGS). In addition to uncovering many novel mutations in the known genes, we identified novel genes associated with CH.
Subjects and Methods

Patients
Fifty-five patients from 47 families were enrolled in the study. They were referred from various regional hospitals in Saudi Arabia. Diagnosis of CH was made on the basis of persistent high serum TSH and low serum free thyroxine levels. Diagnosis of thyroid dysgenesis or dyshormonogenesis was based on the technetium-99m pertechnetate thyroid scintigraphy or ultrasonography. The perchlorate discharge test is not routinely performed. A patient with a goiter or normal thyroid was considered to have thyroid dyshormonogenesis (30 patients). Thyroid dysgenesis was diagnosed in patients with no thyroid, ectopic thyroid, or smaller thyroid (25 patients). Patients with Down syndrome were excluded. The study was approved by the institutional review board of King Faisal Specialist Hospital and Research Centre, and written informed consent was obtained from the patients and/or their parents.
DNA sequencing
Genomic DNA from peripheral blood leukocytes was extracted, and libraries were constructed for exome enrichment and capture using Agilent's SureSelect V5 Whole Exome Capture kit according to the manufacturer's instructions (Santa Clara, CA). NGS was performed on an Illumina HiSeq 2000 with 503 coverage by standard Illumina protocol (San Diego, CA). All the candidate mutations were verified by Sanger sequencing.
In silico analysis of variants
The significance of single nucleotide variants of unknown significance (VUSs) was predicted using the following four webbased programs: Mutation Taster (http://www.mutationtaster. org), PolyPhen-2 (http://genetics.bwh.harvard.edu/pph2/), SIFT (http://sift.jcvi.org/), and PROVEAN (http://provean.jcvi.org/ index.php). VUSs were considered to be mutations if they had low allelic frequency (,0.01) in the normal population database, were predicted to be damaging or disease causing by at least three of four prediction programs, and were present only in the patient or in strict segregation with the phenotype in familial cases. Biallelic mutations were considered diseasecausing mutations. Monoallelic mutations in genes with recessive inheritance were still considered VUSs unless they were inherited as compound heterozygotes or were present in two genes known to cause CH.
Results
Identification of disease-causing genes in thyroid dyshormonogenesis
Among 30 patients with thyroid dyshormonogenesis, mutations were identified in 18 patients (60%), including four known genes (TG, TPO, DUOX2, and SLC26A4) and one novel gene (SLC26A7) that encodes for an anion exchanger [ Fig. 1 ; Supplemental Fig. 1(A) ; Table 1 ]. Twelve patients were homozygous for TG mutations (40%; 12 of 30), the most common genetic defect. The TG p.C1476R was present in five patients from three unrelated families, a possible founder effect in the Saudi population. A biallelic TPO mutation was found in two patients and a DUOX2 mutation in one patient. A monoallelic SLC26A4 mutation was found in two patients: one with two tandem biallelic deletions in SLC26A7, the other with two monoallelic mutations in the DDB1-and CUL4-associated factor 17 gene (DCAF17) ( Fig. 1; Supplemental Fig. 2 ; Table 1 ). Although a monoallelic SLC26A4 mutation alone may not cause CH, it may contribute to a more severe phenotype in patient 43.1 with two tandem biallelic SLC26A7 mutations or to disease development in patient 7 with two monoallelic DCAF17 mutations (see the following text and discussion). Sequencing analysis of candidate genes. Both patients are homozygous for the double SLC26A7 deletions (c.927_930delCACT, p.I309Mfs*9 and c.932_933delAA, p.E311Gfs*28) in exon 9 of SLC26A7. Their parents and brothers are heterozygous carriers. The c.927_930delCACT predicts frameshift and a premature stop codon nine amino acids from the mutation. The c.932_933delAA predicts frameshift and a premature stop codon 28 amino acids from the mutation. Both patients and their mother are heterozygous carriers of TG p.R32H VUS (c.95G.A in exon 2). The proband, her mother, and her brother-2 are heterozygous carriers of the SLC26A4 p.I455F mutation (c.1363A.T in exon 12). Mutations are indicated by an arrow. WT, wild-type.
Most mutations were novel, including three in TG (c.2176+1G.A, p.C1476R, and p.Q2432X); one in TPO (p.E413Sfs*38); one in DUOX2 (p.M883I); two in SLC26A7 (p.I309Mfs*9 and p.E311Gfs*28); and two in DCAF17 (p.Y86H and p.C507R) ( Table 1 ). These novel mutations were predicted to be pathogenic by in silico analysis using four prediction programs (Table 2) . Because parental DNA was not available, it was not clear whether patient 7 (Table 1 ) was a compound heterozygote or carried two DCAF17 mutations in one allele. Five monoallelic VUSs in TG (p.L1063M), DUOX2 (p.R101L and p.P609S), and DUOX1 (p.R370H and p.Q1029H) were found in five patients (Supplemental Fig. 2 ; Table 1 ). Given the autosomal recessive nature of the disease and the absence of other known disease-causing mutations in these patients, they were not considered to be causative mutations on their own. Other, as yet unknown genes may be involved. Novel SLC26A7 mutation in thyroid dyshormonogenesis We encountered a family with two patients with CH (43.1 and 43.3; Table 1 ). The elder sister (43.1) developed a goiter at the age of 3 years as a result of persistent highly fluctuating serum TSH values (TSH, 0.14 to 30 mU/L; normal range: 0.5 to 5 mU/L; FT 4 , 14.7 to 28 pmol/L; normal range: 11 to 24 pmol/L), requiring frequent adjustment of levothyroxine dosage (50 to 100 mg/d). Her younger sister (43.2) was also affected but was successfully treated with 25 mg/d of levothyroxine. No goiter development was observed. Their parents and two brothers were normal. Initial exome sequencing of the two patients revealed a novel monoallelic TG VUS (p.R32H) in both patients and a previously reported monoallelic SLC26A4 mutation (p.I455F) in the elder patient only (Table 3) . Sanger sequencing analysis of family members demonstrated that their mother carried both monoallelic TG p.R32H VUS and SLC26A4 p.I455F mutations, indicating that they were unlikely to be the disease-causing mutations (Fig. 1) . Subsequently, we performed exome sequencing of the remaining family members (parents and two brothers) to help identify the causative gene. As shown in Fig. 1 and Table 3 , only three candidate genes (VPS13B, C20orf202, and SLC26A7) fit our filtering criteria: allele frequency ,0.01 in the normal population database, predicted to be damaging by at least three prediction programs, and biallelic variants present only in the patient (strict segregation of variants with disease phenotype). VPS13B encodes a potential transmembrane protein that may function in vesicle-mediated transport and sorting of proteins within the cell. Mutations in VS13B have been associated with Cohen syndrome, characterized by developmental delay, intellectual disability, microcephaly, and hypotonia (22) . VPS13B could be ruled out because of the absence of these clinical features. C20orf202 has an unknown function. SLC26A7 is an anion transporter (chloride and iodide) and belongs to the same family as SLC26A4 (23) . Slc26a7-deletion mice have developed hypothyroidism with hyperplastic changes in thyroid histology (24) , distal renal tubular acidosis, and impairment of gastric acid secretion (23) . On the basis of clinical data and gene function, the SLC26A7 mutation was the most likely candidate gene, although renal and gastric problems were not observed in our patients. The two tandem SLC26A7 deletions (located next to each other) are unusual in our patients. Either deletion of p.I309Mfs*9 or p.E311Gfs*28 would cause a frameshift and premature stop codon nine or 28 amino acids downstream from the mutation, respectively. This would result in complete loss of protein function, resembling Slc26a7 knockout mice. It appears to be redundant to have both deletions.
Identification of disease-causing genes in thyroid dysgenesis
Among 25 patients with thyroid dysgenesis, 10 patients (40%) had mutations in five known disease-causing genes (TSHB, TSHR, NKX2-1, PAX8, and CDCA8). All of them were novel mutations: TSHR (p.R274W and p.R519H), TSHB (p.E32K), NKX2-1 (p.264_265insGGG and p.A254Tfs*85), PAX8 (p.R49H), and CDCA8 (c.585-1G.C) [Supplemental Fig. 1(B) ; Table 1 ]. Six patients were homozygous for TSHR mutations (24%; 6 of 25), the most common genetic defect in thyroid dysgenesis. Interestingly, TSHR p.R519H was detected in four patients from three unrelated families, and p.R274W was detected in two unrelated patients. All of the mutations were predicted to be pathogenic by in silico analysis (Table 2) . Three mutations were found in the genes that play important roles in thyroid development, although their mutations have not been reported in patients with CH: T-box 1 (TBX1) (p.M10T), homeobox D3 (HOXD3) (p.E364G), and homeobox B3 (HOXB3) (p.S181Y). Monoallelic TBX1 c.29T.C and HOXD3 c.1091A.G were found in one patient each. It remains to be determined whether one mutant allele is sufficient to cause disease. The biallelic HOXB3 mutation (c.541_542AG.TA) resulted in an amino acid change from serine to tyrosine (p.S181Y) and was detected in one patient. It might be a causative mutation (Supplemental Fig. 2 ; Table 1 ). If HOXB3 was included as a causative gene, the mutation detection rate for thyroid dysgenesis would increase to 44% (11 of 25).
Discussion
We performed a comprehensive mutation screening of Saudi patients with CH by using NGS. The overall mutation rate was 52.7% (29 of 55): 60% (18 of 30) for thyroid dyshormonogenesis and 44% (11 of 25) for thyroid dysgenesis. Most of the mutations were novel and biallelic. TG and TSHR mutations are the most frequent genetic defects in thyroid dyshormonogenesis and dysgenesis, respectively. The TSHR mutation rate in our 55 patients was 10.9% (6 of 55), which is substantially higher than the 1.6% reported for Chinese patients (25) . In contrast to biallelic TSHR mutations in our patients, all the TSHR mutations were monoallelic in the Chinese patients studied. Monoallelic TSHR mutations by themselves may not cause disease. Interestingly, monoallelic mutations in TG or DUOX2 are often found together with TSHR mutations (25) . Indeed, Nicholas et al. (26) and Löf et al. (27) reported digenic mutations (mutations in two genes) among several known CH-causing genes (TG and TPO, SLC26A4 and TPO, SLC26A4 and TG, and DUOX2 and TG) in patients from ethnically diverse families. Digenic biallelic DUOX1 and DUOX2 mutations have also been reported in CH (28) . It remains unclear whether monoallelic mutations in two genes cause disease or contribute to more severe disease phenotypes. It has been reported that monoallelic mutations in SLC26A4 and the K + channel gene KCNJ10 results in nonsyndromic hearing loss associated with enlarged vestibular aqueduct, providing evidence of monoallelic mutations in two genes in disease development (29) . In the current study, we did not observe digenic variants in known CH-causing genes, probably because of the consanguineous nature of the population. The two Saudi patients from the study by Nicholas et al. (26) were homozygotes for TG R159*. Unlike DUOX2 mutations, which are frequently found in Korean and Chinese patients (30, 31) , TG and TSHR mutations are the most common genetic defects found in Saudi patients with dyshormonogenesis and dysgenesis, respectively. Given that TG p.C1476R and TSHR p.R519H are frequently detected and have not been reported in other populations, they may be founder mutations unique to the Saudi population.
TSHR mutations at p.R519C and p.R519G were reported previously in Japanese patients with TSH resistance (32) . The p.R519C has also been reported in Korean patients with CH (33) . The p.R519H in our patient is located in the same codon as previously reported cases and is likely pathogenic. A nonsense TSHB mutation (p.E32*) has been described in three patients with congenital TSH-deficient hypothyroidism (34) . The biallelic TSHB mutation (p.E32K) in our patient is a missense mutation located in the same codon. Because the TSHR mutation at codon R519 and the TSHB mutation at codon E32 occur in multiple patients, these locations are likely important for protein structure and function.
TBX1 encodes T-box transcription factor TBX1, a central player in the coordinated formation of organs derived from the pharyngeal apparatus and adjacent heart field. Its inactivation results in DiGeorge syndrome/ velo-cardio-facial syndrome, for which thyroid dysgenesis may be a feature (35) . Haploinsufficiency of TBX1 is thought to cause the phenotype (36) . Tbx1 knockout mice develop thyroid hemiagenesis/dysgenesis (37) . Our patient, who carries the novel monoallelic TBX1 mutation (p.M10T), has only ectopic thyroid and does not have congenital heart defects. Although the variant is predicted to be pathogenic, its significance remains undetermined.
The novel biallelic HOXB3 mutation (p.S181Y) found in patient 47 (Table 1) was not present in either ExAC or 1000G and was predicted to be damaging by all four prediction programs. HOXB3 activates transcription of the TTF-1 transcription factor encoded by the NKX2-1 gene (38) . Hoxa3 knockout results in thyroid agenesis in mice. Although thyroid dysgenesis is not observed in Hoxb3 or Hoxd3 knockout mice, the absence of these genes can exacerbate thyroid defects caused by Hoxa3 knockout (39) . A monoallelic HOXD3 mutation (p.E364G) was also identified in a patient with dysgenesis (patient 25; Table 1 ). Given that thyroid development is normal in Hoxd3 knockout mice, its role in human thyroid development remains undetermined.
PAX8 directly regulates transcription of TG, TPO, and NIS by binding to their specific promoters (40) . Homozygous mutant mice develop thyroid aplasia (41) . In contrast to the normal phenotype in heterozygous mutant mice (41) , monoallelic PAX8 mutations are usually found in patients and are inherited in an autosomal dominant manner as a result of haploinsufficiency and/or dominant negative effects (42, 43) . To our knowledge, biallelic PAX8 mutations have not been reported in the literature. The biallelic R49H mutant found in our patient (37; Table 1 ) is next to a previously reported S48F mutant that shows half of wild-type PAX8 transcriptional activity and a dominant negative effect on wild-type PAX8 (44) . The R49H mutant would probably result in complete loss of PAX8 transcriptional activity. Although we are unable to evaluate the parents of the patient, they may either have mild hypothyroidism or be a heterozygous carrier. It has been reported that monoallelic PAX8 mutations can have an incomplete penetrance (45).
The novel monoallelic DCAF17 mutations (p.Y86H and p.C507R) are present in a patient (7; Table 1 ) who also carries a previously reported monoallelic SLC26A4 mutation (p.G497S) (19) . DCAF17 encodes a nuclear transmembrane protein that associates with cullin 4A/ damaged DNA binding protein 1 ubiquitin ligase complex. Loss-of-function mutation causes WoodhouseSakati syndrome, characterized by hypogonadism, alopecia, diabetes mellitus, mental retardation, and extrapyramidal syndrome (46) . Hypothyroidism is often present in these patients. Mutations (nonsense, splicing, or deletion) predicted to cause complete loss of its function are present in patients who are homozygous or compound heterozygous for DCAF17 (47) . Missense mutations have not been reported in patients with WoodhouseSakati syndrome. It is tempting to speculate that the missense mutations found in our patient may retain partial function, causing only hypothyroidism with or without participation of or interaction with the SLC26A4 mutation.
The identification of SLC26A7 mutation in patients with thyroid dyshormonogenesis is one of the major discoveries in our study. Several findings support the causative role of SLC26A7 in the pathogenesis of the disease: (1) the complete segregation of the mutation with disease phenotype; (2) absence of the mutation in the normal population; and (3) hypothyroidism with hyperplastic thyroid changes in mice with Slc26a7 deletion. Both SLC26A4 and SLC26A7 are anion transporters capable of chloride and iodide transport. Until now, only NIS (SLC5A5) and SLC26A4 mutations have been found to cause thyroid dyshormonogenesis due to iodide transport defects (48, 49) . Further studies are needed to elucidate the mechanism by which SLC26A7 leads to decreased thyroid hormone synthesis. Like SLC26A4, SLC26A7 mutation may result in defective iodide efflux from the apical membrane of thyrocytes into the follicular lumen, leading to thyroid dyshormonogenesis. However, at this point, no formal evidence supports SLC26A7-mediated apical iodide efflux.
Interestingly, in the transcriptome analysis of thyroid vs nonthyroid tissues, Vitale et al. (50) have demonstrated that TG, TPO, and SLC26A7 are the top three genes overexpressed in the thyroid compared with nonthyroid tissues (ratio = 188.22 for TG, 151.17 for TPO, and 66.94 for SLC26A7) followed by IYD (ratio = 66.25), TSHR (ratio = 49.36), and SLC26A4 (ratio = 44.46). Although our findings may point to a primary role for SLC26A7 in thyroid hormone synthesis, other mechanisms cannot be entirely ruled out. Apart from SLC26A4, several other candidate genes have been considered for thyroid iodide efflux, including ANO1, CLCN5, CFTR, and SMCT1, although this remains controversial (51, 52) .
Another interesting gene is KCNE2, whose protein forms a potassium channel with KCNQ1. KCNE2 is required for NIS-mediated iodide uptake, most likely by maintaining the membrane potential of thyroid epithelial cells (49, 53) . Although Kcne2-deletion mice have impaired thyroid iodide accumulation, hypothyroidism, goiter, and cardiac abnormalities (54) , KCNE2 mutation in humans causes only cardiac arrhythmia or long QT syndrome (55) .
The current study identified SLC26A7 as a member of a family of genes associated with thyroid dyshormonogenesis, although the mechanism remains undefined. Hypothyroidism caused by SLC26A7 mutations cannot be rescued by wild-type SLC26A4 or SLC5A5, suggesting that SLC26A4, SLC5A5, and SLC26A7 are all required for thyroid hormone synthesis. It is worth mentioning that one of our patients (43.1; Table 1 ) has a goiter and a fluctuating serum TSH level that is difficult to control by thyroxine replacement therapy. The patient also carries a monoallelic SLC26A4 mutation (p.I455F), which was reported previously in two patients with deafness (56) . Although our patient has no hearing loss, the SLC26A4 mutation may contribute to more severe clinical symptoms, such as goiter formation and persistent high/fluctuating serum TSH level due to loss of SLC26A4-mediated apical iodide efflux.
In summary, TG and TSHR mutations are the most common genetic defects in Saudi patients with CH. The mutation spectrum is quite unique and narrow, mainly concentrated in the TG and TSHR genes, which may reflect the consanguineous nature of the population. SLC26A7 mutations appear to be associated with thyroid dyshormonogenesis.
